PR002904 (Project)

Dcc Asset:

MW submission packet 20260310.zip

Processed File (Entity type)

Dcc:

Metabolomics

DCC (Entity type)

Child Project:

PPR00001

Project (Entity type)

Persistent Id:http://dx.doi.org/10.21228/M8984Z

Description:Cystic fibrosis (CF) is characterized by severe metabolic and lipid dysregulation driven by chronic inflammation, oxidative stress, and CFTR dysfunction. The primary aim of this study is to assess the biochemical effects of three CFTR modulator therapies Trikafta® elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta®), Symdeko® tezacaftor/ivacaftor (TI; Symdeko®), and Orkambi® lumacaftor/ivacaftor (LI; Orkambi®) in plasma samples from CF patients through untargeted metabolomic and lipidomic analyses.

Results found

Linked to

	Label	Description
	SA545876 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project
	SA546013 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project
	SA546023 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project
	SA545944 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project
	SA545991 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project
	SA545941 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project
	SA545961 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project
	SA545900 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project
	SA546004 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project
	SA545940 Biosample (Entity type)	A biosample from Metabolomics produced as part of the PR002904 project